Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06800339
Title	A Phase I, Single-Arm, Single-Institution Study Evaluating Neoadjuvant Chemoimmunotherapy with Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer (NEORADJUVANT)
Acronym	NEORADJUVANT
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	University of Maryland, Baltimore
Indications	lung non-small cell carcinoma
Therapies	Carboplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab
Age Groups:	senior \| adult
Covered Countries	USA